Grifols (GRFS) Current Deferred Revenue (2016 - 2025)
Grifols (GRFS) posted Current Deferred Revenue of $31.4 million for Q4 2025, down 18.3% quarter-over-quarter from $38.5 million in Q4 2024, and down 18.3% year-on-year from $38.5 million in Q4 2024.
Grifols (GRFS) Current Deferred Revenue (2016 - 2025) Analysis & Trends
Grifols (GRFS) has reported Current Deferred Revenue for 10 consecutive years, with $31.4 million the latest figure, recorded in Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $31.4 million, down 18.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.4 million (down 18.3% YoY), and the FY2025 annual result was $31.4 million, down 18.3% from the prior year.
- Current Deferred Revenue was $31.4 million for Q4 2025 at Grifols, down from $38.5 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $38.5 million in Q4 2024 and troughed at $28.2 million in Q4 2022.
- Average Current Deferred Revenue over 5 years is $33.4 million, with a median of $31.4 million recorded in 2025.
- Year-over-year, Current Deferred Revenue soared 37.93% in 2021 and decreased 25.23% in 2022.
- Over 5 years, Current Deferred Revenue stood at $37.7 million in 2021, then fell by 25.23% to $28.2 million in 2022, then grew by 10.14% to $31.1 million in 2023, then climbed by 23.85% to $38.5 million in 2024, then slipped by 18.3% to $31.4 million in 2025.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $31.4 million in Q4 2025, $38.5 million in Q4 2024, and $31.1 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.43 Mn |
| Dec 31, 2024 | 38.47 Mn |
| Dec 31, 2023 | 31.06 Mn |
| Dec 31, 2022 | 28.20 Mn |
| Dec 31, 2021 | 37.72 Mn |
| Dec 31, 2020 | 27.34 Mn |
| Dec 31, 2019 | 10.84 Mn |
| Dec 31, 2018 | 10.17 Mn |
| Dec 31, 2017 | 5.04 Mn |
| Dec 31, 2016 | 476,158.38 |